Obese men have higher-grade and larger tumors: An analysis of the duke prostate center database

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 3, 2009, Pages 259-263

  Freedland, S J ^a,b   Banez L L ^a,b   Sun, L L ^b   Fitzsimons, N J ^b   Moul, J W ^b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEGRO; OBESITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; TUMOR BIOPSY; TUMOR VOLUME;

BODY MASS INDEX; DATABASES, FACTUAL; HUMANS; MALE; OBESITY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 70249099520     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.11     Document Type: Article

References (22)

1. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol 2005; 174: 919-922.
2. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L et al Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004; 22: 439-445.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
4. Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB et al. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 2005; 174: 1798-1801.
5. Jayachandran J, Aronson WJ, Terris MK, Presti Jr JC, Amling CL, Kane CJ et al. Obesity and positive surgical margins by anatomic location after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. BJU Int 2008.
6. Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll PR et al Effect of BMI on primary treatment of prostate cancer. Urology 2008; 72: 406-411.
7. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS et al Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-181.
8. Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS,Wan F et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006; 296: 2683-2693.
9. Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006; 17: 5-9.
10. Freedland SJ, Sun L, Kane CJ, Presti Jr JC, Terris MK, Amling CL et al. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int 2008; 102: 969-974.
11. Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol 2008; 180: 571-576 discussion 576.
12. Freedland SJ, Terris MK, Platz EA, Presti Jr JC. Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology 2005; 66: 108-113.
13. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983.
14. Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 2007; 177: 102-106; discussion 106.
15. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-158.
16. Bray GA. The underlying basis for obesity: Relationship to cancer. J Nutr 2002; 132: 3451S-3455S.
17. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E et al. Insulin receptor expression by human prostate cancers. Prostate 2009; 69: 33-40.
18. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 2008; 9: 1039-1047.
19. Hammarsten J, Hogstedt B. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887-2895.
20. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005; 14: 1262-1269.
21. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005; 23: 8152-8160.
22. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298: 2275-2280.